摘要:

AbstractSixteen patients with metastatic carcinoma of the colon were treated with a regimen of leucovorin 200 mg/m2, given as a 10-min infusion followed by a median dose of 833 mg/m2(range 500–1000 mg/m2) 5-fluorouracil every two weeks. For the 16 patients with proven metastatic disease, two-year survival exceeds 50%. Responses were: 2 complete; 4 partial; 4 minor; 3 progression; and 3 not evaluable but without progression to date. Toxicities included: 8 (50%) leukopenia; 9 (56%), 1 severe, thrombocytopenia; 9 (56%), 2 severe, diarrhea; 9 (56%), 3 severe, nausea/vomiting; 8 (50%), 1 severe, stomatitis; 7 (44%) conjunctivitis; 6 (38%) alopecia; and 13 (81%), 3 severe, neurotoxicity. Leucovorin appears to exert a dose-dependent beneficial effect on both the response and survival produced by the intermittent high dose 5-fluorouracil schedule. This benefit first appears to increase substantially when the leucovorin dose is increased from 120 to 200 mg/m2. Findings identify a testable candidate regimen for selected good risk patients. Full selection criteria remain to be identified.

ISSN:0735-7907    

DOI:10.3109/07357909009012048

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractTwenty-two consecutive patients with brain metastases from breast carcinoma were treated with a combination of platinum (100 mg/m2day 1) and etoposide (100 mg/m2days 4,6,8) every three weeks. Five (23%) achieved a complete response (CR) while 7 (32%) obtained a partial response (PR) for an overall response rate of 55%. The 95% confidence interval for combined CR and PR was 34–76%. Five patients received brain irradiation after reaching the maximum degree of objective remission by chemotherapy. Median duration of combined CR plus PR was 40 weeks (12 + 152). Median duration of survival was 58 weeks (2; 208+). Fifty-five percent of the patients were alive at one year. Our study demonstrates that this combination treatment is highly effective in the management of brain metastases from breast carcinoma.

ISSN:0735-7907    

DOI:10.3109/07357909009012049

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractTwenty-four patients with refractory Stage IV breast cancer were teated with platinol (100 mg/m2i.v. Day 1) and 5-fluorouracil (1000 mg/m2as a continuous infusion over 24 h daily for 5 days). Objective responses occurred in 12 of 24patients (50%). The median duration of response was 4.9 months. Platinol and 5-fluorouracil in combination are active agents in patients with refractory breast cancer, and clinical trials are warranted in previously untreated patients.

ISSN:0735-7907    

DOI:10.3109/07357909009012050

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractFour single-arm trials using methotrexate (M), 5-fluomuracil (5FU), and leucovorin (L) were sequentially performed in metastastic measurable colorectal cancer using different dosing and timing schedules for the three drugs. A total of 99 patients were entered into the trials, 92 (49 men and 43 women) of whom were evaluable for response. Although the first trial appeared to have a 36% response rate, the overall response rate seen in the four trials was not higher than historical reports of 5FU alone. We could find no correlation with dose intensity or patient characteristics to account for the apparent good results of the first trial. It is our conclusion that MFL is not an active combination in colorectal cancer. After progressing to the fourth trial, four patients were placed on 5FU alone (supported by a grant from Lederle, Canada). This resulted in one response in a patient who had not responded to the three-drug combination and stable disease in two patients previously progressing. Although there are many reports of this combination working, the possibility is raised that M may be inhibitory to the combination despite the in vitro data.

ISSN:0735-7907    

DOI:10.3109/07357909009012051

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractThirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 mm prior to 5FU. All patients had a good performance status, bidimensionally measurable disease, and weight loss≤5% of preillness weight. Of the 29 evaluable patients, only two (7%) had partial responses (95% confidence limits 1–24%). Eleven (38%) had stable disease and 16 (55%) progressed. The two responding patients survived 12 and 60+ weeks. The median survival of all evaluable patients was 25 weeks (range 7–60+) and that of the stable patients was 26 weeks. The principal toxicities observed were diarrhea and stomatitis. Myelosuppression was rarely dose limiting. In contrast to the results of treatment with 5FU and folinic acid in metastatic colorectal cancer and breast cancer, the results of treatment with this combination of agents have been much less encouraging in adenocarcinoma of the lung.

ISSN:0735-7907    

DOI:10.3109/07357909009012052

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractThe diagnostic validity of the glycolytic enzyme phosphohexose isomerase (PHI) as a serum tumor marker was evaluated. For this purpose the sensitivity of PHI was determined in 435 patients with histopathologically defined, malignant gastrointestinal, kidney, and mammary tumors prior to primary treatment. To assess the specificity, PHI serum activities were measured in 181 patients with benign diseases and disorders from an internal practice. In gastrointestinal and kidney cancer, PHI reached an overall diagnostic sensitivity of about 70%, and a specificity of 92% was obtained. Even in early stages without metastasis, elevated PHI serum levels were found in about 60% of the patients. In mammary cancer, however, a sensitivity of only 40% was observed. PHI activity can be measured without the need for highly technical skills and equipment, in a short time and at low cost. These data suggest that serum PHI can be a useful indicator in the preventive checkup of gastrointestinal and renal cancer in medical practice.

ISSN:0735-7907    

DOI:10.3109/07357909009012053

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractTo assess the influence of computed tomography of the thorax (CTT) in management of patients with lymphoma, we compared results of CTT and chest radiography (CXR) for 42 patients (65 examinations) with Hodgkin 's disease (HD) with 48 patients (57 examinations) with non-Hodgkin lymphoma (NHL). Six percent (7/122) of all CTs resulted in major changes in patient management (95% confidence interval = 2–12%). In four patients with HD, influential findings included identification of additional sites of lymphoma and clarification of x-ray results. In three patients with NHL (5%), management was altered as a result of identification of additional sites of lymphoma on CTT. Eleven percent of CTT examinations clarified equivocal CXR findings in NHL, and management was affected in two of these cases. Our findings suggest that CTT is valuable in clarifying equivocal CXR findings, and in staging or restaging patients for whom the detection of mediastinal adenopathy would affect patient treatment.

ISSN:0735-7907    

DOI:10.3109/07357909009012054

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractMultiple transforming growth factors (TGFs) capable of conferring the neoplastic phenotype on NRK-49F cells without the addition of any other exogenous growth factor in the soft agar assay, were purified from two human solid malignant neoplasms: a squamous lung carcinoma and a pectoral rhabdomyosarcoma. In both tumors, low-molecular-weight transforming activities (4000–6000) that were not potentiated by epidermal growth factor (EGF), competed for binding to the EGF receptor, possessed mitogenic activity on NRK fibroblasts arrested in serum-deprived medium, and did not show inhibitory effects on DNA synthesis induced by EGF and insulin in NRK cells. Other TGFs with molecular weights 9000 to 48,000, were also found in the malignant tissues examined; these TGFs, were not potentiated by EGF, did not compete for binding to the EGF receptor, were not mitogenic for NRK cells, and acted as potent inhibitors of DNA synthesis induced by EGF and insulin in NRK cells. These results demonstrate that growth-promoting activities, and modulating agents that can act as either enhancers or inhibitors of cell proliferation, are present in neoplastic tissues of different embryologic origin and histologic type.

ISSN:0735-7907    

DOI:10.3109/07357909009012055

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909009012056

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909009012057

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor